Iodine Software surpasses $1B valuation with strategic growth investment from Advent International

AUSTIN, TX and BOSTON, MA – December 1, 2021 – Iodine Software (“Iodine” or the “Company”), a leading healthcare AI company, today announced a strategic growth investment from Advent International (“Advent”), one of the largest and most experienced global private equity investors. Advent will acquire a significant stake in Iodine in a transaction that values the business at over $1 billion. Bain Capital Ventures (“BCV”) and Silversmith Capital Partners (“Silversmith”), which invested in the Company in 2018, will remain shareholders. Financial terms were not disclosed.

“Utilizing advancing technology to scale hospital resources, ease administrative burden, and maximize reimbursement is more important than ever,” said William Chan, Iodine’s CEO and co-founder. “We’ve always been committed to building the most powerful, predictive tools available. This investment provides access to capital for expansion and growth strategies so that we can innovate faster and find more ways to empower healthcare leaders to meet with confidence the delicate balance of quality, efficiency, and system financial resilience.”

Iodine Software provides the leading clinical AI solution for highly accurate capture of patient documentation. The Company’s platforms are trusted by more than 800 hospitals and are used by more than 80,000 healthcare providers nationwide.

Iodine’s AwareCDI solution recently received the top overall performance score in the 2021 KLAS Clinical Documentation Improvement Report. The company also recently completed the acquisitions of Artifact Health and ChartWise to broaden its market reach, bolster its portfolio and deliver a comprehensive query transformation solution that solves a critical physician pain point.

“We are pleased to be partnering with Iodine Software as it continues to experience rapid growth across hospitals and health systems,” said Carmine Petrone, a Managing Director on Advent’s Healthcare team. “Iodine’s world-class AI innovation engine and strong customer focus underpin the company’s ability to deliver a best-in-class product with highly differentiated value.” Lauren Young, a Managing Director on Advent’s technology team, added: “With our extensive experience scaling software and healthcare businesses, we look forward to working with Bain Capital Ventures and Silversmith Capital Partners to support William and the entire Iodine team to continue driving innovation and building a leading AI/machine learning-driven revenue cycle management platform.”

This investment will empower Iodine to invest further in its AI engine, CognitiveML, to power new and additional products in other strategic areas of care delivery for health systems.

“We were excited to partner with the founders of Iodine back in 2018 as their first institutional investor, and are even more thrilled to partner with Advent and the Iodine team to support the next phase of growth,” said Jeff Crisan, Managing Partner at Silversmith Capital Partners. Yumin Choi, partner at Bain Capital Ventures, added, “We saw the enormous potential its AI-powered software would provide to hospitals going through digital transformations. With this strategic investment, Iodine will have the opportunity to reach more hospital professionals, resulting in better care for patients across the US.”

Over the past 30+ years, Advent has invested or committed more than $11 billion in 88 technology companies and $10 billion in 51 healthcare companies, including health tech, software and provider businesses.

Deutsche Bank served as exclusive financial advisor to Iodine and Queen Saenz + Schutz PLLC served as the Company’s legal advisors. For Advent, Evercore and TripleTree served as financial advisors and Weil, Gotshal & Manges LLP served as legal counsel.